Palisade Bio (PALI)
NASDAQ:PALI
PALI Stock Chart & Stats
$1.96
-$0.36(-15.79%)
At close: 4:00 PM EST
$1.96
-$0.36(-15.79%)
Day’s Range― - ―
52-Week Range$0.53 - $2.64
Previous CloseN/A
Volume307.14K
Average Volume (3M)4.53M
Market Cap
$325.13M
Enterprise Value$191.82M
Total Cash (Recent Filing)$133.38M
Total Debt (Recent Filing)$71.00K
Price to Earnings (P/E)―
Beta-0.18
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding165,884,810
10 Day Avg. Volume4,196,076
30 Day Avg. Volume4,525,639
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-191.82K
Enterprise Value/Ebitda-10.62
Forecast
1Y Price Target
$10.67Price Target Upside444.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker And Tissue EvidenceEarly clinical biopsy and biomarker data showed downregulation of inflammatory and fibrosis gene programs and improved tissue markers, supporting a biological effect beyond symptom relief.
Targeted Drug DesignColon-targeted prodrug design concentrates active PDE4 inhibition in the lower intestine to reduce systemic exposure, potentially increasing local effectiveness while limiting systemic side effects.
Unmet Medical NeedAbsence of approved therapies for fibrostenotic Crohn's disease highlights a clear market opportunity if proof-of-concept studies confirm anti-fibrotic benefit.
Bears Say
Clinical, Regulatory And Financing RiskClinical, regulatory, and financing uncertainties remain significant and could delay development or commercialization even if early signals appear promising.
Data Robustness And Trial DesignSmall, open-label datasets limit confidence in results and raise the risk that observed benefits may not reproduce in larger, placebo-controlled trials.
Microbiome-dependent Activation RiskDependence on bacterial activation in the lower gut means inflammation or microbiome changes could alter drug activation and exposure, creating unpredictable efficacy and tolerability.
Palisade Bio News
PALI FAQ
What was Palisade Bio’s price range in the past 12 months?
Palisade Bio lowest stock price was $0.53 and its highest was $2.64 in the past 12 months.
What is Palisade Bio’s market cap?
Palisade Bio’s market cap is $325.13M.
When is Palisade Bio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Palisade Bio’s earnings last quarter?
Currently, no data Available
Is Palisade Bio overvalued?
According to Wall Street analysts Palisade Bio’s price is currently Undervalued.
Does Palisade Bio pay dividends?
Palisade Bio does not currently pay dividends.
What is Palisade Bio’s EPS estimate?
Palisade Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palisade Bio have?
Palisade Bio has 165,884,810 shares outstanding.
What happened to Palisade Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Palisade Bio?
Currently, no hedge funds are holding shares in PALI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palisade Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (444.39% Upside)
$10.67 (444.39% Upside)
Blogger Sentiment
Bullish
PALI Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $17.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 14.5%
Last 30 Days ▲ 14.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.46%
12-Months-Change
Fundamentals
Return on Equity
-228.64%
Trailing 12-Months
Asset Growth
-25.31%
Trailing 12-Months
Company Description
Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
PALI Stock 12 Month Forecast
Average Price Target
$10.67
▲(444.39% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Eledon Pharmaceuticals
―
―
Orchestra BioMed Holdings
―
Pyxis Oncology
―
Ownership Overview
0.04% Insiders
3.00% Mutual Funds
54.66% Other Institutional Investors
41.13% Public Companies and Individual Investors
Options Prices
Currently, No data available
---